Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-immunogenic recombinant staphylokinase in intermediate high-risk pulmonary embolism
NCT06362746Phase 3Recruiting
- Sponsor
- SuperGen, Inc.
- Start
- May 2024
- Primary completion
- Jun 2028
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary embolism (PE) comparing Non-immunogenic recombinant staphylokinase with Placebo (2 arms). Primary endpoint: Composite of death from any cause or hemodynamic collapse or recurrent pulmonary embolism at 30 days. Started May 2024; status: recruiting.
02
Drugs
staphylokinase
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT06362746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362746.